NDA 212271 · Meitheal
Contepo
Fosfomycin Disodium · Intravenous
Priority reviewLast checked: Nov 19, 2026Latest source record: Oct 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Oct 22, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
9
3 Phase 3, 1 recruiting
FAERS reports
4
4 serious, 2 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 4, 2025.
CONTEPO is an epoxide antibacterial indicated for the treatment of patients 18 years of age and older with complicated urinary tract infections (cUTI) including acute pyelonephritis caused by susceptible isolates of Escherichia coli and Klebsiella pneumoniae . ( 1.1 ) Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of CONTEPO and other antibacterial drugs, CONTEPO should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) 1.1 Complicated Urinary Tract Infections (cUTI), including Acute Pyelonephritis CONTEPO is indicated for the treatment of patients 18 years and older with complicated urinary tract infections (cUTI), including acute pyelonephritis, caused by susceptible isolates of Escherichia coli and Klebsiella pneumoniae . 1.2 Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of CONTEPO and other antibacterial drugs, CONTEPO should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Mechanism: CONTEPO is an antibacterial drug [ see Microbiology ( 12.4 ) ] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- CONTEPO · FOSFOMYCIN DISODIUM EQ 6GM BASE/VIAL · POWDER, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Fosfomycin Disodium" as an intervention, any sponsor and status, largest first.
- Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP InfectionsPivotal-lookingCompleted
Nabriva Therapeutics AGIndustry
NCT02753946 · 465 participants · Start Apr 2016 · Primary completion Jan 12, 2017
Drug: ZTI-01; Piperacillin-tazobactam · For: Urinary Tract Infection Symptomatic; Acute Pyelonephritis; Urinary Tract Infection Complicated
Sites: Pensacola, Florida; Augusta, Georgia; Columbus, Georgia · 68 sites in all
- Fosfomycin Versus Meropenem or Ceftriaxone in Bacteriemic Infections Caused by Multidrug Resistance in E.ColiPivotal-lookingCompleted
Fundación Pública Andaluza para la gestión de la Investigación en SevillaAcademic, hospital or other
NCT02142751 · 161 participants · Start Jul 2014 · Primary completion Dec 2018
Drug: Fosfomycin sodium intravenous; Meropenem intravenous and 1 more · For: Infection Due to ESBL Escherichia Coli
Sites: Terrassa, Spain; Las Palmas de Gran Canaria, Spain; Vilanova, Spain · 22 sites in all
- A Combination Therapy With Ceftazidime and Fosfomycin Will be Compared to Ceftazidime Alone in Hospitalized Adult Patients With Suspected Severe Gram-negative Bacterial InfectionsPivotal-lookingRecruiting
Angela HUTTNERAcademic, hospital or other
NCT07063095 · 100 participants (planned) · Start Aug 25, 2025 · Primary completion Dec 2026
Drug: Ceftazidime± avibactam with fosfomycin; Ceftazidime± avibactam with placebo · For: Gram Negative Infections; Sepsis and Septic Shock
Sites: Geneva, Switzerland
Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranAcademic, hospital or other
NCT03235947 · 82 participants · Start Sep 7, 2016 · Primary completion Nov 6, 2017
Drug: Fosfomycin disodium; Trimethoprim / Sulfamethoxazole and 1 more · For: Urinary Tract Infection; Asymptomatic Bacteriuria
Sites: Mexico City, Mexico
Nabriva Therapeutics AGIndustry
NCT03709927 · 41 participants · Start Jan 11, 2018 · Primary completion Apr 12, 2018
Drug: ZTI-01; Moxifloxacin 400mg · For: Cardiac Repolarization in Healthy Subjects
Sites: Baltimore, Maryland
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT03910673 · 39 participants · Start Jun 27, 2019 · Primary completion Dec 17, 2020
Drug: Fosfomycin disodium · For: Bacterial Infection; Multiple-drug Resistance; Pathogen Resistance
Sites: Durham, North Carolina
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT02178254 · 30 participants · Start Aug 2014 · Primary completion Oct 2014
Drug: Fosfomycin tromethamine; Fosfomycin disodium · For: Pseudomonas Infection
Sites: Overland Park, Kansas
Zealand University HospitalAcademic, hospital or other
NCT04312360 · 28 participants · Start Jan 16, 2020 · Primary completion Apr 13, 2022
Drug: therapeutic endoscopy with metronidazole and fosfomycin disodium · For: Right-sided Colon Cancer; Right-sided Colon Adenoma
Sites: Copenhagen, Denmark; Køge, Denmark
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- acute kidney injury2
- ascites2
- chills2
- contusion2
- cystitis2
- dry mouth2
- fatigue2
- gastroenteritis2
- haematuria2
- lipase increased2
- liver function test increased2
- malignant neoplasm progression2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2025 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections: A Randomized Clinical Trial.
Sojo-Dorado J, López-Hernández I, Rosso-Fernandez C, et al. · JAMA Netw Open 2022 · Multicenter Study, Randomized Controlled Trial
- Perioperative fosfomycin disodium prophylaxis against urinary tract infection in renal transplant recipients: a randomized clinical trial.
Rosado-Canto R, Parra-Avila I, Tejeda-Maldonado J, et al. · Nephrol Dial Transplant 2020 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous (ZTI-01) and Oral Fosfomycin in Healthy Volunteers.
Wenzler E, Ellis-Grosse EJ, Rodvold KA · Antimicrob Agents Chemother 2017 · Clinical Trial, Phase I, Randomized Controlled Trial
Sponsor: Meitheal
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.